     30 issues
      1 bluewater
      1 2724
      1 nondefence
<<CONTENT>>
profits slide at indias dr reddy

profits at indian drugmaker dr reddys fell 93% as research costs rose and sales flagged

the firm said its profits were 40m rupees 915000; 486000 for the three months to december on sales which fell 8% to 47bn rupees dr reddys has built its reputation on producing generic versions of bigname pharmaceutical products but competition has intensified and the firm and the company is short on new product launches the most recent was the annoucement in december 2000 that it had won exclusive marketing rights for a generic version of the famous antidepressant prozac from its maker eli lilly it also lost a key court case in march 2004 banning it from selling a version of pfizers popular hypertension drug norvasc in the us research and development of new drugs is continuing apace with r&d spending rising 37% to 705m rupees  a key cause of the decrease in profits alongside the fall in sales patents on a number of wellknown products are due to run out in the near future representing an opportunity for dr reddy whose shares are listed in new york and other indian generics manufacturers

sales in dr reddys generics business fell 86% to 966m rupees another staple of the the firms business the sale of ingredients for drugs also performed poorly sales were down more than 25% from the previous year to 14bn rupees in the face of strong competition both at home and in the us and europe dr reddys indian competitors are gathering strength although they too face heavy competitive pressures
